Kuros Biosciences was granted FDA 510(k) clearance to market MagnetOs Putty as a standalone bone graft in the extremities and pelvis. This is in addition to the existing clearance for use of MagnetOs Granules and MagnetOs Putty as an autograft extender in posterolateral spine.
MagnetOs was previously cleared in the U.S. in a granule format under its manufacturer, Xpand Biotechnology, which was acquired by Kuros in 1Q17. Kuros intends to expand into other orthopaedic applications, such as reconstructive surgery.
Kuros Biosciences was granted FDA 510(k) clearance to market MagnetOs Putty as a standalone bone graft in the extremities and pelvis. This is in addition to the existing clearance for use of MagnetOs Granules and MagnetOs Putty as an autograft extender in posterolateral spine.
MagnetOs was previously cleared in the U.S. in a granule format...
Kuros Biosciences was granted FDA 510(k) clearance to market MagnetOs Putty as a standalone bone graft in the extremities and pelvis. This is in addition to the existing clearance for use of MagnetOs Granules and MagnetOs Putty as an autograft extender in posterolateral spine.
MagnetOs was previously cleared in the U.S. in a granule format under its manufacturer, Xpand Biotechnology, which was acquired by Kuros in 1Q17. Kuros intends to expand into other orthopaedic applications, such as reconstructive surgery.
Copy to clipboard 
